Mersana Therapeutics Reports Positive Interim Data from the Expansion Portion of the XMT-1536 Phase 1 Study
- Achieved 35% objective response rate, including 10% complete response rate, and 80% disease control rate among twenty evaluable patients with ovarian cancer
- Data continue to support a NaPi2b biomarker-based patient selection strategy
- Generally well-tolerated with no new safety signals
- Data to be presented on a conference call today at
“These data demonstrate not only that XMT-1536, our first-in-class Dolaflexin ADC targeting NaPi2b, can deliver confirmed complete responses, partial responses and durable stable disease in platinum-resistant ovarian cancer, but also that these responses can deepen over time in a patient population with poor prognosis and limited treatment options,” said
The expansion portion of the Phase 1 study is enrolling patients with platinum-resistant ovarian cancer, fallopian tube or primary peritoneal cancer who have received up to three lines of prior therapy and in some cases four lines of prior therapy regardless of platinum status as well as patients with NSCLC adenocarcinoma who had received prior treatment with platinum-based therapy and immunotherapy or targeted agents. With a data cutoff of
| • | Safety profile consistent with previously reported dose escalation data and no new safety signals observed. | ||||||||
| ◦ | The most frequently (≥20%) reported treatment-related adverse events (TRAEs) were Grade 1-2 fatigue, nausea, vomiting, pyrexia, decreased appetite, diarrhea and fever and transient AST elevation without associated changes in bilirubin or cases of Hy’s law. | ||||||||
| ◦ | There were no reported cases of severe neutropenia, peripheral neuropathy or ocular toxicity. | ||||||||
| • | Promising antitumor activity observed in platinum-resistant ovarian cancer. | ||||||||
| ◦ | Of the 20 patients that were evaluable for response, 2/20 (10%) achieved confirmed complete responses (CRs) and 5/20 (25%) achieved confirmed partial responses (PRs) for an objective response rate (ORR) of 35%. Additionally, 1/20 (5%) patients achieved an unconfirmed partial response for which a confirmatory scan was pending at the time of the data cutoff, and 8/20 (40%) patients achieved stable disease (SD); the disease control rate (DCR) was 16/20 (80%). | ||||||||
| ◦ | The majority of responders had prior treatment with bevacizumab, PARP inhibitors, or both. Both patients with confirmed complete responses had prior treatment with bevacizumab and PARP inhibitors. | ||||||||
| • | Data continue to support a NaPi2b biomarker-based patient selection strategy. | ||||||||
| ◦ | An emerging biomarker-response relationship continues to be observed. For consistency, these data were bifurcated using the same expression level as used in the dose escalation portion of the study. More data are needed to define the patient selection strategy. | ||||||||
| ▪ | Among those patients with higher NaPi2b expression, two (2/14) patients achieved a CR, and two (2/14) achieved a PR. | ||||||||
| ▪ | Two (2/2) patients with NaPi2b expression not yet determined at the time of data cutoff achieved confirmed PRs. | ||||||||
| ▪ | One (1/4) patient with lower NaPi2b expression (H-score of 90) achieved a confirmed PR. | ||||||||
| ▪ | The Company expects to define the patient selection strategy based on the total data set from patients treated with XMT-1536. | ||||||||
| Response - Ovarian Cancer N=20* | All | Higher NaPi2b o | Lower NaPi2b oo | NaPi2b Not Yet Determined |
| N | 20 | 14 | 4 | 2 |
| CR | 2 (10%) | 2 (14%) | 0 (0%) | 0 (0%) |
| PR | 5 (25%) | 2 (14%) | 1 (25%) | 2 (100%) |
| uPR** | 1 (5%) | 1 (7%) | 0 (0%) | 0 (0%) |
| SD | 8 (40%) | 7 (50%) | 1 (25%) | 0 (0%) |
| PD | 4 (20%) | 2 (14%) | 2 (50%) | 0 (0%) |
*7 patients not evaluable: 1 withdrew consent (Lower NaPi2b Expression); 1 with unrelated SAE leading to discontinuation and death (Lower NaPi2b Expression); 5 have not yet received a scan
**uPR=1 patient with unconfirmed PR; confirmatory scan pending at the time of data cut
° Higher NaPi2b Expression: defined in dose escalation as at / above lowest H-score at which response observed (≥110)
°° Lower NaPi2b Expression: defined in dose escalation as below the lowest H-score at which response observed (<110)
| • | More data are needed to assess antitumor activity of XMT-1536 in NSCLC adenocarcinoma patients. | |||||
| ◦ | At the time of data cutoff, four out of seven NSCLC adenocarcinoma patients were evaluable for response, and 2/4 (50%) patients had achieved SD as best response. | |||||
Conference Call Details
About
Forward-Looking Statements
This press release contains “forward-looking” statements within the meaning of federal securities laws. These forward-looking statements are not statements of historical facts and are based on management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning the Company’s business strategy and the design, progression and timing of its clinical trials and expectations regarding future clinical results based on data achieved to date. Forward-looking statements generally can be identified by terms such as “aims,” “anticipates,” “believes,” “contemplates,” “continues,” “could,” “estimates,” “expects,” “goal,” “intends,” “may,” “on track,” “plans,” “possible,” “potential,” “predicts,” “projects,” “seeks,” “should,” “target,” “will,” “would” or similar expressions and the negatives of those terms. Forward-looking statements represent management’s beliefs and assumptions only as of the date of this press release. The Company’s operations involve risks and uncertainties, many of which are outside its control, and any one of which, or combination of which, could materially affect its results of operations and whether the forward-looking statements ultimately prove to be correct. Factors that may materially affect the Company’s results of operations and whether these forward-looking statements prove to be correct include, among other things, that preclinical testing or early clinical results may not be predictive of the results or success of ongoing or later clinical trials, and that the development and testing of the Company’s product candidates will take longer and/or cost more than planned, as well as those listed in the Company’s Annual Report on Form 10-K filed with the
Contact:
Investor & Media Contact
617-844-8577
scarmody@mersana.com
Source: Mersana Therapeutics, Inc.